NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a #lifescience portfolio company dedicated to bringing breakthrough treatments to patients in #oncology, #autoimmunediseases, and #womenshealth, today announced that it is expanding its bifunctional #antibody #pipeline to include a novel PD-1 x VEGF tetravalent #bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) and other solid tumors. NAYA is leveraging its proprietary FLEX antibody platform and further optimizing its design through a #partnership with #MabSilico, an #artificialintelligence & deep technology-focused company, to accelerate the development of new best-in-class candidates for validated therapeutic targets. “We are excited to add a novel, #AI-optimized PD-1 x VEGF therapeutic candidate to our pipeline of best-in-class bifunctional antibodies,” President Dr. Daniel Teper. “NAYA’s bifunctional format has demonstrated the ability for synergistic dual-targeting activity, resulting in the potential to unlock clinical response in solid tumors.”
